SL
BMRN icon

Savior LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

Savior LLC’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-53
Closed -$4K – 255
2021
Q2 		$4K Hold
53
– – ﹤0.01% 597
2021
Q1 		$4K Hold
53
– – ﹤0.01% 612
2020
Q4 		$5K Buy
+53
New +$4.2K ﹤0.01% 541
2020
Q1 		– Sell
-114
Closed -$10K – 808
2019
Q4 		$10K Buy
+114
New +$8.61K 0.01% 423

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Savior LLC's BMRN Position: Q3 2021 in Review

Savior LLC sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 53 shares — an estimated $4K sold.

Savior LLC first reported a position in BMRN in Q4 2019 and held it in 4 quarters. The position peaked at $10K in Q4 2019. 511 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

  • Savior LLC reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Savior LLC sold 53 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $4K.
  • Savior LLC first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • Savior LLC's BioMarin Pharmaceuticals position peaked at $10K in Q4 2019.
  • 511 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Savior LLC's 13F filing for Q3 2021, filed 5 Oct 2021.